Anti-CD3
Showing 1 - 25 of >10,000
Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed
Not yet recruiting
- Pediatric Cancer
- +11 more
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
-
Milwaukee, WisconsinChildren's Wisconsin
Sep 14, 2022
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
Colorectal Cancer, Cancer of Pancreas, Pancreatic Tumor Trial in Detroit (FOLFOX6, EGFRBi armed ATC Infusions)
Completed
- Colorectal Cancer
- +7 more
- FOLFOX6
- EGFRBi armed ATC Infusions
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Mar 30, 2022
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma (MZL)
- Odronextamab
- +2 more
-
Chiang Mai, ThailandChiang Mai University
Nov 20, 2023
Follicular Lymphoma (FL) Trial in Noblesville (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Follicular Lymphoma (FL)
- Odronextamab
- +5 more
-
Noblesville, IndianaInvestigative Clinical Research of Indiana
Oct 18, 2023
Follicular Lymphoma (FL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Follicular Lymphoma (FL)
- Odronextamab
- +6 more
-
Westbury, New YorkClinical Research Alliance Inc
Oct 13, 2023
Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)
Withdrawn
- Leukemia
- Stem Cell Transplantation
-
Munich, Bavaria, Germany3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022
Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)
Not yet recruiting
- Relapsed Refractory Multiple Myeloma
- REGN5458
- +3 more
- (no location specified)
Feb 6, 2023
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Diffuse Large B-cell Lymphoma (DLBCL)
- Odronextamab
- +5 more
-
Westbury, New YorkClinical Research Alliance Inc
Oct 13, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023
Breast Cancer Female, Leptomeningeal Metastases Trial in Charlottesville (HER2 BATs)
Terminated
- Breast Cancer Female
- Leptomeningeal Metastases
- HER2 BATs
-
Charlottesville, VirginiaUniversity of Virginia
Dec 15, 2022
Metastatic Breast Cancer Trial in Charlottesville (HER2 BATs with Pembrolizumab)
Recruiting
- Metastatic Breast Cancer
- HER2 BATs with Pembrolizumab
-
Charlottesville, VirginiaAshley Donihee
Jan 18, 2023
Multiple Myeloma Trial in Charlottesville (SLAMF7 BATs)
Not yet recruiting
- Multiple Myeloma
- SLAMF7 BATs
-
Charlottesville, VirginiaUniversity of Virginia
May 17, 2022
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma Trial in Charlottesville (EGFR BATs after
Recruiting
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- EGFR BATs after standard of care chemo
-
Charlottesville, VirginiaUniversity of Virginia
Mar 30, 2022
DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial
Not yet recruiting
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- +2 more
- Biospecimen Collection
- +5 more
- (no location specified)
Sep 5, 2023
Breast Cancer Trial in Detroit (biological, drug, other)
Terminated
- Breast Cancer
- HER2Bi-armed activated T cells
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Nov 29, 2022
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia
Recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Blinatumomab
- +2 more
-
New Haven, Connecticut
- +6 more
Jul 9, 2022
Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023
Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)
Recruiting
- Safety and Efficacy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 27, 2023
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +11 more
- Biopsy
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte
Not yet recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +2 more
- Biopsy
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
May 15, 2023